Abortion pioneer died at 93 in hospital after being diagnosed with dementia
Dr Horace Hale Harvey III, who was born in New Orleans in December 1931, opened one of the first independent abortion clinics in the US in Manhattan in July 1970 after New York State had reformed its laws.
The clinic, called Women's Services, provided safe and affordable abortions.
In an obituary, the New York Times reported that Dr Harvey had become an abortion provider to 'combat what he felt was an epidemic of unsafe abortions at a time when unmarried women were denied access to contraceptives, and when comprehensive sex education was discouraged'.
Dr Harvey, who had a son and a daughter, later moved to the Isle of Wight and worked for public health services there but in 2014 moved to Dorset after his house burned down.
The obituary states that Dr Harvey had chosen the Isle of Wight because 'according to his research, it had the highest average temperature and received more hours of sunlight than anywhere else in England'.
In a statement read to the Bournemouth inquest, his daughter Kate said that her father was 'very determined' to keep healthy by walking a mile and doing 20 squats each day and said he 'enjoyed laughter and making up jokes' as well as activities such as dance, table tennis and snooker.
She added that he was a scholar who was 'committed to Aristotelian ethics and scientific learning'.
The inquest heard that in late 2024, Dr Harvey was diagnosed with Alzheimer's and PTSD after the house fire 10 years earlier.
On January 22 2025, he was taken to Dorset County Hospital having suffered a rib fracture in a fall at home.
After physiotherapists expressed concerns at his ability to understand care instructions, he was assessed by psychiatrists and was detained under the mental health act.
Coroner Richard Middleton said that Dr Harvey was increasingly experiencing delirium and paranoia.
He said that Dr Harvey was found dead in his hospital bed in the early hours of February 14 and a post-mortem examination found he died of natural causes from ischaemic heart disease and coronary artery disease.
The coroner, recording a conclusion of death by natural causes, explained that the inquest had to be held by law because Dr Harvey was formally detained by the state at the time of his death.
Mr Middleton added: 'I express my deepest condolences to all of Dr Harvey's family and friends for their loss.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
24 minutes ago
- Forbes
UnitedHealth Stock Is Being Dumped By Wall Street—Here's Why
UnitedHealth stock is being offloaded. It just reported billions in profit. Earnings were strong. The story sounded stable. Yet the stock has been sinking. It's trading near multi-year lows, underperforming peers, and reacting poorly to every quarterly release. The market doesn't move like this for nothing. Markets often sniff out risks long before they're made official. The headlines are piling up: government investigations, operational failures, and leadership questions, but the price has already started to discount something deeper. Investors are trained to react to numbers. But when structure breaks, the numbers are often the last to go. This isn't about a soft quarter. The model itself is cracking, and the market sees it. The way UnitedHealth generates earnings, the incentives behind its vertical integration, and the regulatory heat all point to fragility that isn't captured in consensus spreadsheets. The market is whispering what many investors don't want to admit: that something is changing here. And once trust fades, the re-rating isn't temporary. It's structural. UnitedHealth Stock: Big, Profitable, Misunderstood UnitedHealth trades with a market value of about $226 billion, against $400 billion in revenue for 2024, with 2025 revenue expected to reach mid‑$445 billion to $448 billion. Size doesn't really equal a safe company; it often hides the fragility beneath. Most investors can't describe how the business works. They see adjusted EPS. They don't question the mechanics. They assume that anything producing this much cash must be built to last. But what looks durable can rot from the inside. The core of UnitedHealth's engine is vertical integration. Optum decides on care, delivers it, and pays itself. One hand washes the other, all under the same roof. It's efficient when unexamined. But regulators are finally paying attention. When the payer, provider, and data all sit in one unit, it becomes harder to separate health outcomes from billing outcomes. Investors often mistake size for insulation. But complexity cuts both ways. When that model starts to wobble, through government probes, whistleblower claims, or unexplained earnings distortions, it doesn't usually collapse overnight. It slowly leaks. This is what we are witnessing. The price action is the tell. This isn't about sentiment anymore. It's about what the market now knows; the market no longer trusts what it thought it understood. You can see it is undone. Slowly at this point. But it's picking up. UnitedHealth Is In The Crosshairs Of The Regulators The Department of Justice now runs both criminal and civil investigations into UnitedHealth's Medicare Advantage billing, officially confirmed on July 24, 2025. Washington is targeting diagnostic coding and risk adjustment practices tied to higher payouts. A process investigators say may have involved pressure, bonuses, and algorithmic recommendations to staff for certain lucrative diagnoses. At the center is Optum, UnitedHealth's massive care delivery and analytics arm, which assigns diagnoses, delivers services, and influences payer reimbursement. That vertical structure underpinned margin expansion until it became a regulatory vulnerability. Congress and CMS are now eyeing those same incentives for bundled services that may prioritize profit over care. And according to multiple reports, lawmakers are drafting reforms to Medicare Advantage to clamp down on what they see as systemic abuse. This is more than a compliance issue. If enforcement leads to fines or limits on Optum's ability to steer claims, UnitedHealth loses both margin and narrative. The company disclosed a potential settlement cost of $1.6 billion tied specifically to these investigations. For investors, this isn't a question of past performance but future structure. If Washington forces a redesign in how payer, provider, and auditor relationships operate within Optum, valuation multiples change. You won't see regulatory risk on a spreadsheet. It's not in the line items. But it's in every fund manager's head. And the market is already pricing that doubt. Earnings Vs. Trust UnitedHealth keeps beating the numbers. But the market's not cheering anymore, and that should make investors stop to think. Second‑quarter 2025 adjusted EPS came in at $4.08, while GAAP net earnings per share were about $3.74, reflecting a 9‑10% spread. This isn't a one-off. The company has leaned on adjustments for several quarters, removing charges from cyberattacks, restructuring, litigation, and 'normalizing' expense items. Each quarter it gets harder to square the adjusted reality with the actual income statement. Investors have tolerated this because the stock used to respond. Now, even beats fall flat. The post-earnings reaction in July was strong, with headline numbers, and yet shares sank over 4%. It's not the earnings they're questioning. It's the whole premise. When the market no longer trusts the adjustment logic, the premium unwinds. At some point, 'adjusted' starts sounding like wishful thinking. That's a dangerous pivot for a stock that trades on perceived consistency. The issue here is credibility. And when credibility gets questioned in a complex, vertically integrated healthcare giant with active DOJ probes and massive opacity in its internal operations, the path forward narrows quickly. UnitedHealth's numbers still impress. But the market is no longer listening to the numbers alone. It's watching what they're trying to cover. Optum: The Black Box That Powered Growth At UnitedHealth For years, Optum was UnitedHealth's crown jewel. It gave the company vertical integration that most healthcare giants could only dream of. Run the insurer. Own the doctor's office. Control the pharmacy benefit manager. Route the claims. Capture every step of the dollar. Investors praised it as genius. Until now. Optum was built for margin expansion. By combining payer and provider, UnitedHealth collapsed the value chain into itself. But that same structure is now drawing fire. Regulators are asking whether a company can truly manage care outcomes and approve and profit from the services being recommended. This questions their entire integration strategy. What used to be pitched as 'scale and efficiency' now looks like opacity. Good luck getting through an Optum report without needing aspirin halfway. It's all intentional. In a market that once rewarded complexity, investors are shifting toward simplicity and transparency. Optum is the opposite. Here's the rub: the more essential Optum is to UnitedHealth's story, the more exposed the company becomes to scrutiny. Break the chain or just shake investor faith in it and the premium vanishes. Optum was once the crown jewel. Now it's the bullseye. The Cyberattack Was A Wake-Up Call At UnitedHealth When Change Healthcare, an Optum subsidiary, was hit by a massive ransomware attack earlier this year, most investors treated it as a one-off disruption. It wasn't. It was a systemic failure that revealed how fragile UnitedHealth's infrastructure had become and how slow its leadership was to respond. The breach paralyzed billing and claims systems for weeks across the U.S. healthcare network. Providers couldn't get paid. Pharmacies stalled. Patients were caught in the middle. For a company that sells itself on reliability and integration, the collapse of a core system fully exposed them to operational risk. But the real damage was reputational. CEO Andrew Witty's delayed response and lack of transparency during the fallout shook investor confidence. For a business model that depends on centralized control, a failure of this scale felt like the opposite of control. The market didn't punish the stock immediately, but the tone shifted. Since the hack, UnitedHealth stock has lagged peers, failed to respond to buybacks, and sold off post-earnings despite beats, indicating trust erosion. In healthcare, operational execution is the product. And the cyberattack told the market what the earnings couldn't: UnitedHealth may be bigger than ever, but its foundation isn't as solid as the numbers suggest. Defensive Stocks Are No Longer Safe Havens Investors once treated UnitedHealth like a bond proxy. It was dependable, defensive, and cash-rich, perfect in a zero-rate world, but the world has moved on. And the assumptions that supported its premium are unraveling with it. But investors have moved on. Higher rates change everything. Safety no longer commands a valuation premium. If anything, it draws sharper scrutiny. Now, capital seeks efficiency and flexibility. It rotates out of perceived stability the moment cracks appear. That's exactly what's happening with UnitedHealth. It's mainly about multiples. Stocks like UnitedHealth were priced on the assumption that growth would stay steady, margins wouldn't come under pressure, and regulators would remain passive. That's no longer the case. Every part of the thesis, from Medicare Advantage economics to Optum's integration, is under review. And the old multiple doesn't hold under new conditions. At 9 to 10 times forward earnings, UnitedHealth stock is still priced for control. But what happens if growth slows, scrutiny increases, and earnings quality erodes? That multiple doesn't hold when earnings wobble and faith erodes. And that's what we're starting to see. The idea that defensive means safe no longer applies. In a world where capital costs more and scrutiny cuts deeper, structural risk matters more than past predictability. And UnitedHealth is showing investors what happens when they confuse size for safety. Market Behavior Is Telling
Yahoo
30 minutes ago
- Yahoo
These 2 Popular 'Healthy' Snacks Can Actually Increase Dementia Risk, Neuroscientists Warn
These 2 Popular 'Healthy' Snacks Can Actually Increase Dementia Risk, Neuroscientists Warn originally appeared on Parade. While meals are often planned out (to avoid the inevitable 'what's for dinner?' inquiries), snacks tend to be an in-the-moment decision. But just like at meal time, everything you eat or drink impacts the body for better or for worse, including the makes the ready-to-eat snacks you keep on hand extra important. Think about what's in your pantry and fridge right now that are your household's most popular snacks. Even if you make most of your meals using nutrient-rich, whole food ingredients, many people rely on processed, packaged foods for snacks because they're quick and easy. Not all processed foods are unhealthy; some are good for you. However, there is one snack that many people think is healthy, but neurologists say it can increase the risk of dementia when eaten regularly. 🩺SIGN UP for tips to stay healthy & fit with the top moves, clean eats, health trends & more delivered right to your inbox twice a week💊 The 'Healthy' Snacks That Increase Dementia Risk When Eaten Regularly According toDr. Jamey Maniscalco, PhD,a neuroscientist and founder of Manifest Wellness, two snacks that many people think are healthy—but in reality are not good for brain health—are granola bars and flavored yogurt. 'They're often full of added sugars, artificial ingredients and processed oils, while also lacking the fiber, healthy fats and nutrients your brain needs to thrive. When eaten regularly, they can disrupt the way your brain functions and increase the risk for mental and cognitive health problems over time,' he you freak out too much, Dr. Maniscalco says that when only eaten occasionally, these snacks are nothing to worry about. But if added sugar-filled granola bars or flavored yogurt are part of your daily routine, he says that over time they can increase the risk of Dr. Faye Begeti, PhD, a neuroscientist and author of The Phone Fix, also says that ultra-processed foods—which can include granola bars and flavored yogurt—are detrimental to brain health long-term. 'Ultra-processed foods tend to be high in refined sugars and unhealthy fats and typically lack essential nutrients our brains need. Regularly consuming these foods can negatively affect blood sugar control and increase inflammation, both of which are linked to impaired cognitive function, memory issues and a higher risk of dementia later in life,' she explains. Dr. Maniscalco adds to this, saying, 'Inflammation doesn't just affect your joints or your gut; it affects your brain too. Inflammatory chemicals can interfere with how your brain cells communicate, making it harder to focus, regulate emotions and stay mentally sharp.' Scientific research backs this up, showing that regularly consuming ultra-processed foods is linked to a higher risk of dementia. Related: Granola bars and flavored yogurt aren't the only 'healthy' snacks where added sugar can be found. Neurologist and author Dr. David Perlmutter, MD, says that orange juice often contains more sugar than many people realize. 'We often think a glass of orange juice is a healthy way to start the day, but a 12-ounce serving contains an astounding 31 to 39 grams of sugar, comparable to or even exceeding the sugar in a 12-ounce can of Coca-Cola, which has about 39 grams,' he says. Though orange juice has vitamin C, Dr. Perlmutter says that the high sugar content outweighs this benefit. 'It causes a rapid blood sugar spike, triggering insulin release and promoting fat storage and inflammation,' he explains. A healthier way to get your vitamin C? Have an orange. That way, you get the added benefit of fiber and don't get the added sugar that juices contain. Related: Brain-Healthy Snacks To Have Instead It bears repeating that not all processed snacks are unhealthy. Consider this yet another reminder to check the nutritional panel and ingredients list when shopping for snacks. If you want a snack that lowers your risk of dementia instead of increasing it, Dr. Begeti says to choose something high in omega-3 fatty acids. This can include a handful of nuts, edamame or smoked salmon on toast. Maniscalco says that foods high in antioxidants and fiber support short-term and long-term brain health too. Some examples of this include trail mix containing berries and nuts, hummus and veggies and avocado on whole grain toast. Transitioning from eating sugar-filled processed snacks to nutrient-rich snacks can be challenging at first, but Maniscalco says it gets easier over time. 'One of the biggest barriers to switching from ultra-processed snacks to whole-food alternatives is taste. Hyperpalatable foods overstimulate your taste receptors and reward pathways, essentially desensitizing you to natural flavors. As a result, whole foods may initially taste bland or 'off.' But the good news is that your taste buds regenerate every one to two weeks, and your brain adapts too. After even 10 to 14 days of reduced added sugar and processed flavoring, most people report that fruit tastes sweeter, vegetables are more satisfying and cravings diminish. In other words, whole foods start tasting really good—you just need to give your brain and palate time to adjust,' he explains. Making the switch from snacks full of added sugar to ones containing nutrients like omega-3s, fiber and antioxidants will benefit your brain both in the short term and the long term. The key is having them on hand, prepped and ready to eat! Up Next:Sources Dr. Jamey Maniscalco, PhD,neuroscientist and founder of Manifest Wellness Dr. Faye Begeti, PhD, neuroscientist and author of The Phone Fix Dr. David Perlmutter, MD, neurologist and author of The Grain Brain Cookbook, among other books These 2 Popular 'Healthy' Snacks Can Actually Increase Dementia Risk, Neuroscientists Warn first appeared on Parade on Aug 2, 2025 This story was originally reported by Parade on Aug 2, 2025, where it first appeared.
Yahoo
2 hours ago
- Yahoo
Addus HomeCare (ADUS) Q2 Earnings: What To Expect
Home healthcare provider Addus HomeCare (NASDAQ:ADUS) will be reporting results this Monday afternoon. Here's what you need to know. Addus HomeCare missed analysts' revenue expectations by 0.6% last quarter, reporting revenues of $337.7 million, up 20.3% year on year. It was a mixed quarter for the company, with a narrow beat of analysts' sales volume estimates. Is Addus HomeCare a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Addus HomeCare's revenue to grow 20.8% year on year to $346.5 million, improving from the 10.4% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.46 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Addus HomeCare has missed Wall Street's revenue estimates three times over the last two years. Looking at Addus HomeCare's peers in the senior health, home health & hospice segment, some have already reported their Q2 results, giving us a hint as to what we can expect. BrightSpring Health Services delivered year-on-year revenue growth of 15.3%, beating analysts' expectations by 5.2%, and Option Care Health reported revenues up 15.4%, topping estimates by 4.6%. Option Care Health traded down 2.7% following the results. Read our full analysis of BrightSpring Health Services's results here and Option Care Health's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the senior health, home health & hospice stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Addus HomeCare is down 5.3% during the same time and is heading into earnings with an average analyst price target of $136.45 (compared to the current share price of $104.74). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
